المؤلفون: Hopper, Rachel A.¹ rachel.hopper@va.gov, McMahan, Danni M.¹, Jarvis, Kathryn A.¹, Weideman, Rick A.¹

المصدر: Journal of Pharmacy Practice. Oct2024, Vol. 37 Issue 5, p1127-1131. 5p.

مصطلحات موضوعية: *URINARY tract infections, *EMPAGLIFLOZIN, *MYCOSES, *BODY mass index, *HOSPITAL care, *URINARY catheters, *RETROSPECTIVE studies, *DESCRIPTIVE statistics, *VETERANS, *SODIUM-glucose cotransporter 2 inhibitors, *MEDICAL records, *ACQUISITION of data, *TYPE 2 diabetes, *COMPARATIVE studies, *GLYCOSURIA, *DISEASE risk factors

مصطلحات جغرافية: UNITED States

المؤلفون: Maagensen, Henrik^1,2, Hædersdal, Sofie^1,2, Krogh, Jesper^1,3, Hansen, Torben⁴, Knop, Filip Krag^1,2,5, Thuesen, Anne Cathrine Baun^1,4, Vilsbøll, Tina^1,2,5 tina.vilsboell.01@regionh.dk

المصدر: Diabetic Medicine. Oct2024, Vol. 41 Issue 10, p1-4. 4p.

مصطلحات موضوعية: *EMPAGLIFLOZIN, *HOSPITAL care, *TRANSCRIPTION factors, *MATURITY onset diabetes of the young, *SULFONYLUREAS, *GENE expression, *INSULIN resistance, *SODIUM-glucose cotransporter 2 inhibitors, *GLOMERULAR filtration rate

المؤلفون: Zhang, Lin¹, Hua, Zixin², Fang, Zhenwei¹ fangzhenwei@mail.ccmu.edu.cn, Wei, Juanjuan¹, Lin, Yang¹

المصدر: Journal of Clinical Pharmacology. Oct2024, Vol. 64 Issue 10, p1312-1325. 14p.

مصطلحات موضوعية: *MEDICAL information storage & retrieval systems, *EMPAGLIFLOZIN, *GLUCAGON-like peptide-1 agonists, *PATIENT safety, *GLYCOSYLATED hemoglobin, *PLACEBOS, *BODY mass index, *SITAGLIPTIN, *HYPOGLYCEMIC agents, *ORAL drug administration, *META-analysis, *DESCRIPTIVE statistics, *SYSTEMATIC reviews, *MEDLINE, *TYPE 2 diabetes, *DRUG efficacy, *MEDICAL databases, *ONLINE information services, *CONFIDENCE intervals, *BLOOD sugar monitoring, *PHARMACODYNAMICS

المؤلفون: Khani, Elnaz¹, Aslanabadi, Naser², Mehravani, Kazem², Rezaei, Haleh³, Afsharirad, Hoda¹, Entezari-Maleki, Taher^2,3 tentezari@gmail.com

المصدر: American Journal of Cardiovascular Drugs. Sep2024, Vol. 24 Issue 5, p673-684. 12p.

مصطلحات موضوعية: *EMPAGLIFLOZIN, *TROPONIN, *VENTRICULAR ejection fraction, *RESEARCH funding, *STATISTICAL sampling, *PREOPERATIVE care, *TREATMENT effectiveness, *RANDOMIZED controlled trials, *DESCRIPTIVE statistics, *PERCUTANEOUS coronary intervention, *COMPARATIVE studies, *ST elevation myocardial infarction, *PHARMACODYNAMICS

المؤلفون: Kalambokis, Georgios¹ (AUTHOR) gkalambo@uoi.gr, Tsiakas, Ilias¹ (AUTHOR), Filippas-Ntekouan, Sebastien¹ (AUTHOR), Christaki, Maria¹ (AUTHOR), Milionis, Haralampos¹ (AUTHOR)

المصدر: European Journal of Internal Medicine. Dec2024, Vol. 130, p162-164. 3p.

مصطلحات موضوعية: *KIDNEY physiology, *EMPAGLIFLOZIN, *ASCITES, *PILOT projects

المساهمون: Sunita Singh, MD, MSc, FRCPC, Clinician Scientist

المصدر: A Single Arm, Open Label, Pilot Study to Evaluate the Safety and Efficacy of Once Daily 25mg Empagliflozin in Patients on Peritoneal Dialysis With Residual Kidney Function

المؤلفون: Canadian Heart Function Alliance, Accelerating Clinical Trial (ACT) Consortium, Ottawa Heart Institute Research Corporation, Team PHenomenal Hope

المصدر: Feasibility Trial for the Canadian Right Ventricular AdaptiVE (CRAVE) Platform for Therapies Targeting Right Ventricular Failure

المصدر: Open-label, Randomized, Two-period Comparative Pharmacokinetics and Bioequivalence Study of Empagliflozin + Metformin Hydrochloride 5 Mg/1000 Mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 5 Mg/1000 Mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany) in Healthy Volunteers Under Fed Conditions

المؤلفون: Luzerner Kantonsspital, Centre Hospitalier Universitaire Vaudois

المصدر: Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia - a Multicentric Randomized Double-blind Placebo-controlled Trial (the EMPOWER Study)

المؤلفون: Danish Heart Foundation, Herlev and Gentofte Hospital, University Hospital Bispebjerg and Frederiksberg, Hillerod Hospital, Denmark, Rigshospitalet, Denmark

المساهمون: Jacob Moller, Professor, MD, PhD

المصدر: Empagliflozin to Elderly and Obese Patients With Cardiovascular Disease (Empire Prevent: Cardiac): A Randomized Controlled Trial
Reichek N, Wilson J, St John Sutton M, Plappert TA, Goldberg S, Hirshfeld JW. Noninvasive determination of left ventricular end-systolic stress: validation of the method and initial application. Circulation. 1982 Jan;65(1):99-108. doi: 10.1161/01.cir.65.1.99. No abstract available.
Carter-Storch R, Moller JE, Christensen NL, Rasmussen LM, Pecini R, Sondergard E, Videbaek LM, Dahl JS. End-systolic wall stress in aortic stenosis: comparing symptomatic and asymptomatic patients. Open Heart. 2019 Apr 9;6(1):e001021. doi: 10.1136/openhrt-2019-001021. eCollection 2019.

المؤلفون: Danish Heart Foundation, Herlev and Gentofte Hospital, University Hospital Bispebjerg and Frederiksberg, Hillerod Hospital, Denmark, Rigshospitalet, Denmark

المساهمون: Jacob Moller, Professor, MD, PhD

المصدر: Empagliflozin to Elderly and Obese Patients With Cardiovascular Disease (Empire Prevent: Metabolic): A Randomized Controlled Trial

المصدر: EASi-HF Preserved - A Phase III Double-blind, Randomised, Parallel-group Superiority Trial to Evaluate Efficacy and Safety of the Combined Use of Oral Vicadrostat (BI 690517) and Empagliflozin Compared With Placebo and Empagliflozin in Participants With Symptomatic Heart Failure (HF: NYHA II-IV) and Left Ventricular Ejection Fraction (LVEF) ≥40%

Other URLs: https://www.mystudywindow.com/msw/datasharing

المصدر: A Multicenter, International, Randomized, Double-blind, Placebo-controlled Clinical Trial of the Aldosterone Synthase Inhibitor BI 690517 in Combination With Empagliflozin in Patients With Chronic Kidney Disease

Other URLs: https://www.mystudywindow.com/msw/datasharing

المصدر: A Regulatory Non-interventional Study to Monitor the Safety and Efficacy of JARDIANCE® (Empagliflozin 10 mg) in Korean Patients With Chronic Kidney Disease (CKD)

Other URLs: https://www.mystudywindow.com/msw/datasharing

المصدر: A Parallel-group Treatment, Phase 2, Double-blind, Three-arm Study to Assess Efficacy and Safety of Finerenone Plus Empagliflozin Compared With Either Finerenone or Empagliflozin Alone in Participants With Chronic Kidney Disease and Type 2 Diabetes.

المؤلفون: American Society of Clinical Psychopharmacology

المصدر: A Pilot, Phase II, Open-Label, Single-Center Study of Sodium-Glucose Cotransporter-2 Inhibitor Empagliflozin in Major Depressive Disorder

المصدر: Open-label, Randomized, Two-period Comparative Pharmacokinetics and Bioequivalence Study of Empagliflozin + Metformin Hydrochloride 5 Mg/850 Mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy® 5 Mg/850 Mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany) in Healthy Volunteers Under Fed Conditions

المساهمون: Camila Manrique, MD, Professor of Medicine

المصدر: SGLT2 Inhibition as a Therapeutic Strategy to Reverse Arterial Stiffening in Aging

المؤلفون: Eli Lilly and Company

المصدر: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) Study Program
Patorno E, Pawar A, Franklin JM, Najafzadeh M, Deruaz-Luyet A, Brodovicz KG, Sambevski S, Bessette LG, Santiago Ortiz AJ, Kulldorff M, Schneeweiss S. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care. Circulation. 2019 Jun 18;139(25):2822-2830. doi: 10.1161/CIRCULATIONAHA.118.039177. Epub 2019 Apr 8.

المؤلفون: Tanta University

المساهمون: Rehab Werida, Associate Professor

المصدر: Diagnostic and Prognostic Roles of Inflammatory Biomarkers in Coronary Heart Disease and Heart Failure Patients Treated With Empagliflozin.
Konig P, Mayer O, Bruthans J, Seidlerova J, Materankova M, Gelzinsky J, Rychecka M, Karnosova P, Wohlfahrt P, Cifkova R, Filipovsky J. The prognostic importance of subclinical heart failure in stable coronary heart disease patients. Acta Cardiol. 2020 Aug;75(4):329-336. doi: 10.1080/00015385.2019.1590958. Epub 2019 Apr 3.
Eisen A, Benderly M, Behar S, Goldbourt U, Haim M. Inflammation and future risk of symptomatic heart failure in patients with stable coronary artery disease. Am Heart J. 2014 May;167(5):707-14. doi: 10.1016/j.ahj.2014.01.008. Epub 2014 Feb 22.
Held C, White HD, Stewart RAH, Budaj A, Cannon CP, Hochman JS, Koenig W, Siegbahn A, Steg PG, Soffer J, Weaver WD, Ostlund O, Wallentin L; STABILITY Investigators. Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. J Am Heart Assoc. 2017 Oct 24;6(10):e005077. doi: 10.1161/JAHA.116.005077.
Papaioannou V, Pneumatikos I, Maglaveras N. Association of heart rate variability and inflammatory response in patients with cardiovascular diseases: current strengths and limitations. Front Physiol. 2013 Jul 10;4:174. doi: 10.3389/fphys.2013.00174. eCollection 2013.
Williams ES, Shah SJ, Ali S, Na BY, Schiller NB, Whooley MA. C-reactive protein, diastolic dysfunction, and risk of heart failure in patients with coronary disease: Heart and Soul Study. Eur J Heart Fail. 2008 Jan;10(1):63-9. doi: 10.1016/j.ejheart.2007.11.003. Epub 2007 Dec 21.